EML4 and non-small cell lung carcinoma: As shown in Fig 6A, we compared the phosphorylation status of ALK substrates and predicted ALK activity in an EML4-ALK–positive NSCLC cell line (H3122), EML4-ALK–positive NSCLC patient-derived cell line (JFCR-028-3), EML4-ALK-I1171N mutant NSCLC patient-derived cell line (MCC-003) and ALK WT NSCLC cell line (A549).